Tolerability of Grazax-R in Children

Phase 1CompletedNCT00298701

ALK-Abelló A/S50 enrolled

Overview

This trial is performed to assess whether the Grazax-R treatment is safe to use in children aged 5-12 years.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Conditions

Allergy

Interventions

ALK Grass tabletBIOLOGICAL

Eligibility

Sex: ALLMin age: 5 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Grass pollen induced rhinoconjunctivitis * Boys and girls, 5-12 years of age * Positive skin prick test to grass pollen Exclusion Criteria: * Previous treatment with immunotherapy

Locations (1)

Tangstedter Landstrasse 77

Hamburg, Germany

Outcomes

Primary Outcomes

Assessment of safety by recording of adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.